Aptevo Therapeutics (NASDAQ:APVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Trading Up 8.1 %

Shares of NASDAQ APVO opened at $0.77 on Thursday. The business’s 50 day moving average price is $4.79 and its 200 day moving average price is $7.85. Aptevo Therapeutics has a 52 week low of $0.70 and a 52 week high of $91.96.

Institutional Investors Weigh In On Aptevo Therapeutics

A number of large investors have recently bought and sold shares of APVO. Sabby Management LLC acquired a new position in Aptevo Therapeutics in the third quarter valued at approximately $440,000. Armistice Capital LLC acquired a new position in Aptevo Therapeutics in the third quarter valued at approximately $408,000. Citadel Advisors LLC acquired a new position in Aptevo Therapeutics in the fourth quarter valued at approximately $47,000. Cantor Fitzgerald L. P. lifted its holdings in Aptevo Therapeutics by 14.8% in the second quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock valued at $367,000 after acquiring an additional 32,422 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Aptevo Therapeutics in the first quarter valued at approximately $152,000. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.